CBRNE - T-2 Mycotoxins Follow-up

Updated: Mar 09, 2016
  • Author: Chan W Park, MD, FAAEM; Chief Editor: Zygmunt F Dembek, PhD, MPH, MS, LHD  more...
  • Print
Follow-up

Further Inpatient Care

In all suspected cases involving T-2 mycotoxin exposure, admission to the hospital is warranted. Supportive care should be instituted with particular attention to the prevention of superinfection. Depending on the time of exposure and the presenting symptoms, serial lymphocyte count may help identify patients who are immunocompromised.

Next:

Inpatient & Outpatient Medications

Although not proven clinically, a theoretical use exists for administering colony-stimulating factors to patients presenting with bone marrow suppression.

Previous
Next:

Complications

Airway compromise may be observed when the disease process includes significant airway edema or hemorrhage.

Previous
Next:

Prognosis

Prognosis of mycotoxin exposure is difficult to assess, since the amount of toxin in previous human ingestions has not been documented. Death from actual toxin ingestion is much less of a concern than the sequelae of immune compromise and successive infection. This is supported by the documented history of the ingestion version of the disease (ATA). No current literature predicts the outcome of T-2 mycotoxin poisoning.

Previous
Next:

Patient Education

For patient education resources, see the Bioterrorism and Warfare Center, as well as Biological Warfare and Personal Protective Equipment.

Previous